Drug or technology

Antibodies, Monoclonal, Humanized

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 10, 2026 · JOURNAL ARTICLE

Cost-effectiveness analysis of finotonlimab in the treatment of advanced recurrent metastatic head and neck squamous cell carcinoma in China.

Human Vaccines & Immunotherapeutics

Modelling study based on a single trial's survival data, assessing cost-effectiveness in a specific healthcare system; does not itself evaluate clinical outcomes and depends on external trial evidence and assumptions.

PreliminaryYuan Gao Head and Neck Neoplasms Head and Neck Cancer

Reported

Incremental cost (finotonlimab +…$26,072.18

Total cost finotonlimab + chemoth…$36,996.99

Total cost chemotherapy alone$10,924.81

AUG 7, 2026 · JOURNAL ARTICLE

Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland.

Journal of Medical Economics

A rigorous health economic analysis based on a pivotal Phase 3 RCT (KEYNOTE-689) with clear cost-effectiveness results well below the Swiss willingness-to-pay threshold, though grounded in modelling rather than direct trial cost outcomes.

Strong EvidenceDzhumber Ugrekhelidze Neoplasm Staging Head and Neck Neoplasms

Reported

Life expectancy extension1.81 years

Incremental QALYs1.42

ICER (cost per QALY gained)CHF 14,227/QALY gained